President Donald Trump did not, in fact, call in to C-SPAN on Friday using “John Barron” as a fake name, the network said. A man who identified himself with that name called in to C-SPAN after the ...
A pseudonym used by President Donald Trump in the 1980s and 90s popped up on Friday, when an individual identifying as a Republican from Virginia named John Barron called C-SPAN to complain about ...
WASHINGTON — An apparent prankster dialed into C-SPAN Friday using President Trump’s famous pseudonym, “John Barron,” and sporting a remarkably family accent, calling into the public access channel to ...
MILAN — It had been less than 24 hours since a missed jump in the women’s short program had derailed her Olympics, and Amber Glenn was back inside the Milano Ice Skating Arena on Wednesday afternoon, ...
DEAR MISS MANNERS: I moved in with my boyfriend and discovered he has, in my opinion, a rather unusual habit. Not only does he say “bless you” in response to sneezes, but he does so in response to ...
CLIFTON PARK — Cobleskill native Eric Truesdell grew up skating his way through the pipeline of the New York Dynamo ice hockey program, all the while knowing the road would soon end. Teammates became ...
Take-Two Interactive revealed it is pausing development on its Nintendo Switch 2 edition of “Borderlands 4” in its latest quarterly earnings results Tuesday. The title’s Switch 2 release was removed ...
A police force has seen an increase in the number of 999 calls it receives, despite more of a focus on digital communications. Suffolk Police figures for 2025 show that 115,065 emergency calls were ...
The Tennessee Vols made a solid addition to their football program on Sunday afternoon. According to On3's Hayes Fawcett, Miami Hurricanes transfer defensive back Jadais Richard has committed to the ...
SAN FRANCISCO, Jan 16 (Reuters) - More than half a dozen major drugmakers are participating in the Trump administration's speedier review program for new medicines, yet other leading pharmaceutical ...
Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Reviews of Sanofi’s diabetes drug Tzield and Disc Medicine’s blood-disorder medicine bitopertin stalled Tzield pushed back after adverse event reports; bitopertin delayed two weeks amid efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results